超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國華人生物醫藥科技協會 CBA The Chinese Biopharmaceutical Association– USA

美國華人生物醫藥協會(Chinese Biopharmaceutical Association - USA 簡稱 CBA )是一個由生物制藥研究和技術發展領域專業人士創建的非盈利組織。協會成立于1995年，其總部設在馬里蘭州。

成員

政府機構，大學，研究機構以及生物技術和制藥行業工作的華人科學家，研究人員，或教授。

執行委員會

由在生物制藥研究及發展領域和行業監管機構從事研究，監管和專業管理的各階層代表組成。

“CBA-the Bridge of US-China Biopharmaceuticals”

The Chinese Biopharmaceutical Association – USA (CBA) is one of the largest Chinese American professional associations in the US (www.cba-usa.org). Founded in 1995, CBA is an independent, non-political, not-for-profit professional organization led by its elected board of directors, board of advisors and executive committees.

CBA’s primary mission is to bridge biopharmaceutics between US and China. Headquartered in Maryland, CBA currently has more than 700 active members with over 3000 registered individual members, and more than 60 institutional members. Most of the CBA members are from the local biopharmaceutical companies, universities, research institutions, and government agencies. More than 80 percent of the CBA members have doctoral degrees. In addition to members from the US, CBA also has members residing in China, Europe, Canada, Australia, Singapore, and Japan.

Since its inception, CBA has been playing a dynamic role in the Chinese and US biopharmaceutical industries. Each year, CBA organizes or co-organizes a number of specially designed workshops, seminars, meetings, and networking events to meet its members’ career advancement needs. CBA’s signature annual event is its black-tie optional gala where business and academic leaders,entrepreneurs and venture capitalists as well as US and Chinese government officials gather together to discuss opportunities and trend of US-China collaborations on biopharmaceuticals. The most influential event of CBA is its annual conference that attracts hundreds to thousands of attendees each year. Many internationally renowned scientists, business leaders, and high-ranking US and Chinese government officials have attended and spoken at CBA’s annual conferences. Some of those distinguished speakers included, but not limited to, Nobel laureates Drs. K Barry Sharpless (2001), Avram Hershko (2004), Luc Montagnier (2008) and Peter Agre (2012); Mr. James C. Greenwood, President and CEO of Biotechnology Industry Organization (BIO); Dr. Zhu Chen, China’s Minister of Health; and many members of US and Chinese science academies including Drs. Paul Schimmel, Robert C. Gallo, Bernard Roizman and E. Albert Reece.

During the past decade, the Chinese biopharmaceutical industry has grown dramatically, and a variety of advantages have attracted many global pharmaceutical companies to China. To promote collaborations between the Chinese and American biopharmaceutical industries, and to further strengthen CBA's influence in the global biopharmaceutical industry, CBA has strategically stepped up its activities in connecting both industries. Besides hosting professional conferences in the US, CBA has also expanded its activities to China by successfully hosting its 13th, 14th and 17th annual conferences in Shanghai, Guangzhou and Qingdao, respectively. Because of CBA’s constant pursue of its mission and persistent devotion to bridging the US and China biopharmaceutical industries, CBA has gained great reputation in US, China as well as other parts of the world. This is certainly evident by reporting or coverage of CBA’s events and its members by a number of prestigious scientific journals, business magazines or news media such as Nature, Science, Thomson Reuters, CCTV, PR Newswire, BioPortfolio or Bioprocess International.